Education
About Us
Working with TipRanks
Follow Us
Mind Medicine Inc. (MNMD)
:MNMD
MNMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.03 - $12.22
Previous CloseN/A
Volume779.86K
Average Volume (3M)2.62M
Market Cap
$492.79M
Enterprise Value$185.59M
Total Cash (Recent Filing)$20.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Mar 06, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.08
Shares Outstanding73,331,690
10 Day Avg. Volume3,087,077
30 Day Avg. Volume2,621,065
Standard Deviation1.35
R-Squared0.07
Alpha0.29
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-58.69
Enterprise Value/Ebitda-1.96
Forecast
1Y Price Target
$29.50Price Target Upside338.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Mind Medicine News
PremiumCompany Announcements
MindMed to Announce 2024 Financial Results in MarchPremiumCompany Announcements
MindMed to Present at Oppenheimer Healthcare Conference---
Bulls Say, Bears Say
Bulls Say
Financial StabilityMindMed ended 3Q24 with $295M of cash, which should be sufficient to fund operations into 2027.
Regulatory SupportMindMed announced it has secured alignment with the FDA, including a reduction in required treatment session duration to 8 hours, which strengthens the feasibility of MM120 as a commercial therapy.
Bears Say
Market PerceptionMM120 ODT program remains on track and is highly underappreciated by investors.
---
Ownership Overview
2.48% Insiders
5.58% Mutual Funds
24.49% Other Institutional Investors
58.90% Public Companies and Individual Investors
MNMD FAQ
What was Mind Medicine Inc.’s price range in the past 12 months?
Mind Medicine Inc. lowest stock price was $5.03 and its highest was $12.22 in the past 12 months.
What is Mind Medicine Inc.’s market cap?
Mind Medicine Inc.’s market cap is $492.79M.
When is Mind Medicine Inc.’s upcoming earnings report date?
Mind Medicine Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 3 days.
How were Mind Medicine Inc.’s earnings last quarter?
Mind Medicine Inc. released its earnings results on Nov 07, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.277 by $0.097.
Is Mind Medicine Inc. overvalued?
According to Wall Street analysts Mind Medicine Inc.’s price is currently Undervalued.
Does Mind Medicine Inc. pay dividends?
Mind Medicine Inc. does not currently pay dividends.
What is Mind Medicine Inc.’s EPS estimate?
Mind Medicine Inc.’s EPS estimate is -0.29.
How many shares outstanding does Mind Medicine Inc. have?
Mind Medicine Inc. has 73,331,690 shares outstanding.
What happened to Mind Medicine Inc.’s price movement after its last earnings report?
Mind Medicine Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.277. Following the earnings report the stock price went up 12.899%.
Which hedge fund is a major shareholder of Mind Medicine Inc.?
Currently, no hedge funds are holding shares in MNMD
---
Mind Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.50 (338.99% Upside)
$29.50 (338.99% Upside)
Blogger Sentiment
Bullish
MNMD Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 806.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $17.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.60%
12-Months-Change
Fundamentals
Return on Equity
-54.61%
Trailing 12-Months
Asset Growth
125.91%
Trailing 12-Months
Company Description
Mind Medicine Inc.
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
---
MNMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted MindMed's strong financial position and progress towards Phase III trials, while also acknowledging rising R&D expenses and a net loss. The sentiment leans towards positive due to the company's strong cash reserves and clear roadmap for advancing clinical trials.Read More>---
MNMD Stock 12 Month Forecast
Average Price Target
$29.50
▲(338.99% Upside)
Technical Analysis
Best Analysts Covering MNMD
1 Year
1 Year Success Rate
11/21 ratings generated profit
1 Year Average Return
+35.62%
reiterated a buy rating 27 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +35.62% per trade.
---